Lou Gehrig's Disease News and Research

RSS
Lou Gehrig's Disease or Amyotrophic Lateral Sclerosis (ALS) is a neurological disorder characterized by progressive degeneration of motor neuron cells in the spinal cord and brain, which ultimately results in paralysis and death. The disease takes its less-scientific name from Lou Gehrig, a baseball player with the New York Yankees in the late 1920s and 1930s, who was forced to retire in 1939 as a result of the loss of motor control caused by the disease.

In 1991, a team of researchers linked familial ALS to chromosome 21. Two years later, the SOD1 gene was identified as being associated with many cases of familial ALS. The enzyme coded for by SOD1 carries out a very important function in cells: it removes dangerous superoxide radicals by converting them into non-harmful substances. Defects in the action of this enzyme mean that the superoxide radicals attack cells from the inside, causing their death. Several different mutations in this enzyme all result in ALS, making the exact molecular cause of the disease difficult to ascertain.

Recent research has suggested that treatment with drugs called antioxidants may benefit ALS patients. However, since the molecular genetics of the disease are still unclear, a significant amount of research is still required to design other promising treatments for ALS.
Immune and central nervous systems may play a key role in ALS, Mount Sinai researchers report

Immune and central nervous systems may play a key role in ALS, Mount Sinai researchers report

Researchers identify biomarkers that could be targets for novel drugs to treat glioblastoma

Researchers identify biomarkers that could be targets for novel drugs to treat glioblastoma

New initiative focuses on patients with the rarest of gene mutations to develop personalized ALS therapies

New initiative focuses on patients with the rarest of gene mutations to develop personalized ALS therapies

Scientists discover a new class of potential drug targets for neurodegenerative diseases

Scientists discover a new class of potential drug targets for neurodegenerative diseases

Winners of the first CERF Medical Engineering Prize for ALS Research announced

Winners of the first CERF Medical Engineering Prize for ALS Research announced

New cloud-based data resource helps researchers to identify subtypes of ALS

New cloud-based data resource helps researchers to identify subtypes of ALS

Novel experimental drug designed to silence FUS gene may help treat ALS

Novel experimental drug designed to silence FUS gene may help treat ALS

Eikonoklastes completes a license to add novel gene therapy for treating neurodegenerative diseases

Eikonoklastes completes a license to add novel gene therapy for treating neurodegenerative diseases

Model of neuromuscular junction could accelerate new treatments for neuromuscular diseases

Model of neuromuscular junction could accelerate new treatments for neuromuscular diseases

Study offers new insight into the role of tau proteins in ALS pathogenesis

Study offers new insight into the role of tau proteins in ALS pathogenesis

Inflammatory chemicals involved in fat metabolism play key role in ALS, study shows

Inflammatory chemicals involved in fat metabolism play key role in ALS, study shows

Atomic-level imaging of infectious prions reveals new therapeutic targets for untreatable diseases

Atomic-level imaging of infectious prions reveals new therapeutic targets for untreatable diseases

Scientists identify the main components driving amyloid beta-associated synapse degeneration

Scientists identify the main components driving amyloid beta-associated synapse degeneration

Dying patients with rare diseases struggle to get experimental therapies

Dying patients with rare diseases struggle to get experimental therapies

Cedars-Sinai receives $11.99 million from CIRM to launch ALS clinical trial

Cedars-Sinai receives $11.99 million from CIRM to launch ALS clinical trial

Research identifies distinctive inflammatory signature in a genetic form of ALS

Research identifies distinctive inflammatory signature in a genetic form of ALS

Researchers use gene therapy to prevent learning, memory loss in Alzheimer's mouse model

Researchers use gene therapy to prevent learning, memory loss in Alzheimer's mouse model

Targeting brain protein may lead to new therapeutic approaches for neurodegenerative disorders

Targeting brain protein may lead to new therapeutic approaches for neurodegenerative disorders

Researchers identify nonelectrical cells that transition the brain from plasticity to stability

Researchers identify nonelectrical cells that transition the brain from plasticity to stability

Researchers unveil a neuroprotective pathway that suppresses ALS

Researchers unveil a neuroprotective pathway that suppresses ALS